Business
RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening
Cost-Efficient Methodology Aims To Reduce Reliance On Expensive Diagnostic Procedures Such As MRI, CT Scans, PET Scans, and EchocardiogramsAPOLLO BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneering developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development for early detection and treatment of eye and systemic diseases, has entered into an agr
About this update from Labcorp Holdings Inc.
[{"type":"image","alt":"RetinalGeniX Technologies, Inc.","displaySize":"","headline":null,"caption":"RetinalGeniX Technologies, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":139,"url":"https://media.zenfs.com/en/globenewswire.com/d4ad793efadb622d7d691fcdbd4e0e9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/R67xr_TcBBfKJTiRgfLQew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d4ad793efadb622d7d691fcdbd4e0e9a","width":300,"height":139}},"lazy":false},{"type":"text","content":"Cost-Efficient Methodology Aims To Reduce Reliance On Expensive Diagnostic Procedures Such As MRI, CT Scans, PET Scans, and Echocardiograms","length":139,"tagName":"p"},{"type":"text","content":"APOLLO BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneering developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development for early detection and treatment of eye and systemic diseases, has entered into an agreement with LabCorp, one of the nation’s largest laboratory services organizations, to support the rollout of the RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform. This innovative program enables patients to undergo genetic testing and high-resolution retinal imaging anonymously and provide insights into both ocular and systemic diseases.","length":722,"tagName":"p"},{"type":"text","content":"Through this collaboration, patients may visit any USA-based LabCorp location to have blood, tears, nasal secretions, and saliva collected and analyzed using proprietary algorithms developed by the RetinalGenix and DNA/RNA GPS analysis platform. These tests may correlate genetic and retinal biomarkers seeking to establish a new standard for early detection of a wide range of health conditions. Based on tests recommended by RetinalGenix, patients may elect to have their data analyzed using specific algorithms developed by RetinalGenix. This process is paired with DNA/RNA/GPS to correlate with current and future biomarkers found in the eye and the blood.","length":660,"tagName":"p"},{"type":"text","content":"Dr. Larry Perich, DO, Advisor for the DNA/RNA/GPS program, noted, “As the database of disease-associated biomarkers expands, we...